Should I now be treating male partners routinely when managing recurrent BV?

Concurrent male-partner treatment is not yet part of standard Australian clinical guidelines for BV. The 2025 study showing over 60% recurrence reduction was a landmark finding, but the evidence base is still developing and formal guideline updates have not been issued. If your patient has recurrent BV with a regular male partner and standard treatment has repeatedly failed, it is a reasonable clinical conversation to have — and a referral to a sexual health physician or clinic may be appropriate to discuss the latest evidence-based options. eTG Therapeutic Guidelines on STIs is the current AU reference standard for management.

My patient has recurrent BV despite completing every course correctly — what else can we try?

Recurrent BV — three or more episodes per year — is a recognised clinical problem with limited current solutions under standard guidelines. Options include extended antibiotic courses (oral metronidazole or clindamycin), topical metronidazole maintenance, and vaginal pH management. Emerging strategies under investigation include concurrent partner treatment, biofilm-disrupting agents, and live biotherapeutic approaches to restore lactobacilli-dominant vaginal flora. If standard approaches have failed, referral to a sexual health specialist or clinic with recurrent BV expertise is appropriate — particularly where the patient has a regular partner who has not been assessed.

Why bacterial vaginosis keeps coming back — and what new research is changing

Bacterial vaginosis recurs in more than half of treated women within three to six months. For women with ongoing regular partners, that rate climbs to between 60 and 80 per cent. Melbourne researchers are now working to understand why — and what to do differently.

A new paper published in The Lancet by researchers from Monash University and Melbourne Sexual Health Centre identifies two distinct pathways driving recurrence: re-infection from an external source, and persistence of the causative bacteria despite treatment. The distinction matters clinically, because the intervention that makes sense for one pathway is different from what works for the other.

The re-infection pathway — and why partners matter

BV has long been discussed as a condition rather than an infection in the sexually transmitted sense, and that framing has shaped clinical practice: treatment has historically been directed at the patient only. A 2025 study changed that conversation.

Concurrent male-partner treatment reduced BV recurrence by over 60 per cent — a finding that, if it holds in larger trials, would represent a significant shift in how recurrent BV is managed for women with regular male partners. The mechanism proposed is that penile microbiome carriage of BV-associated bacteria sustains re-infection, even after successful treatment of the vaginal flora.

This is not yet standard practice in Australia, and it is not reflected in current eTG Therapeutic Guidelines. Concurrent partner treatment sits in the evidence-gathering phase, not the guideline-implementation phase. But for a patient who has completed multiple courses correctly and continues to relapse, it is the kind of option that a referral to a sexual health specialist opens access to.

The persistence pathway — biofilm and bacteria

The second recurrence pathway involves bacterial persistence: the causative organisms — primarily Gardnerella vaginalis and other anaerobic bacteria — are not fully eliminated by antibiotic treatment. One reason for this is biofilm formation. Gardnerella forms thick biofilms on vaginal epithelial cells that protect bacteria from antibiotic penetration. Antibiotics may resolve symptoms and shift the detectable microbial balance, but fail to eradicate the biofilm-protected reservoir.

Addressing this pathway requires different tools: biofilm-disrupting agents currently under investigation, novel antibiotic combinations, and extended-duration treatment regimens. None of these have yet reached Australian clinical guidelines.

Both-and: a genuinely undertreated condition, and a structural problem with simple solutions

BV is undertreated in at least two senses. First, the clinical framing has historically minimised its impact. Dr Sara Whitburn, Chair of the RACGP Specific Interests Sexual Health Medicine group, describes BV as “often very distressing” — affecting self-esteem and relationship quality, not merely a microbiome inconvenience. A patient who has had four or five recurrences in a year, completed every course correctly, and continued to relapse is not experiencing a minor irritation. The cumulative impact on sexual health, relationships, and wellbeing is substantial.

Second, the existing treatment toolkit has limited efficacy against recurrence regardless of how well it is applied. Metronidazole and clindamycin clear acute episodes. They do not reliably prevent what comes next. The research being published now is mapping the mechanism of treatment failure — not asking whether patients are taking their tablets.

The both-and that matters here is: the existing evidence base supports prescribing what we currently have, and the emerging research is genuinely shifting the frame. Those two things sit side by side. Current treatment is not wrong; it is incomplete.

The antimicrobial resistance concern is real and runs in the background. Dr Whitburn names it explicitly — optimising antibiotic use and balancing it against resistance pressures is part of the clinical calculus. The interest in live biotherapeutics (preparations promoting lactobacilli-dominant vaginal flora) is partly driven by the desire to reduce dependence on long-term antibiotic maintenance.

2 cents

For most patients presenting with an initial BV episode, standard management per eTG remains the appropriate starting point. What this research sharpens is the management of patients who have already failed standard treatment repeatedly.

The operational shift is: recurrent BV with a regular partner is a different clinical problem from a first episode, and it deserves a different conversation. That conversation — about the 2025 concurrent-partner treatment evidence, about sexual health specialist referral, about what is on the research horizon — is one most patients with recurrent BV have never had.

If you have a patient in this position, the referral pathway to a sexual health clinic or physician is a meaningful step. The Melbourne Sexual Health Centre research team is actively recruiting; a referral to a clinic engaged in this work gives patients access to trial eligibility assessment.

The prognosis for recurrent BV is not fixed. The research being done now is mapping what actually drives it, and that mapping is the precondition for treatments that work durably rather than transiently.

Verdict: maybe — current treatment guidelines unchanged, but the emerging evidence on re-infection and concurrent partner treatment is worth discussing with patients with recurrent BV.

Sources cited

Researchers pursue lasting treatment for recurrent BV — newsGP / RACGP